These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 31679044)

  • 21. The question of dose for gadolinium chelates in magnetic resonance imaging.
    Runge VM; Kirsch JE; Wells JW; Dunworth JN; Woolfolk CE
    Invest Radiol; 1994 Jun; 29 Suppl 2():S154-6. PubMed ID: 7928215
    [No Abstract]   [Full Text] [Related]  

  • 22. Safety of gadodiamide injection in two different age groups.
    Högström B; Kristoffersen DT; Lundby B; Svaland MG
    J Magn Reson Imaging; 1996; 6(1):255-7. PubMed ID: 8851438
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nonionic contrast media open new paths for MRI.
    D'Agincourt L
    Diagn Imaging (San Franc); 1990 May; 12(5):90-6. PubMed ID: 10183698
    [No Abstract]   [Full Text] [Related]  

  • 24. Severe anaphylactoid reaction after i.v. Gd-DTPA.
    Weiss KL
    Magn Reson Imaging; 1990; 8(6):817-8. PubMed ID: 2266810
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MR contrast enhancement of intracranial lesions with Gd-DTPA.
    Hesselink JR; Press GA
    Radiol Clin North Am; 1988 Jul; 26(4):873-87. PubMed ID: 3289078
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Case of anaphylaxis and four cases of allergic reaction following Gd-DTPA administration.
    Salonen OL
    J Comput Assist Tomogr; 1990; 14(6):912-3. PubMed ID: 2229566
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Use of Omniscan (gadodiamide) in magnetic resonance studies of the central nervous system (results of a multicenter study)].
    Sinitsyn VE; Kornienko VN; Nikitin VG; Pronin IN; Ternovoĭ SK; Tiutin LA; Iakobson MG
    Vestn Rentgenol Radiol; 1995; (4):5-11. PubMed ID: 8571538
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety review of gadopentetate dimeglumine. Extended clinical experience after more than five million applications.
    Niendorf HP; Alhassan A; Geens VR; Clauss W
    Invest Radiol; 1994 Jun; 29 Suppl 2():S179-82. PubMed ID: 7928222
    [No Abstract]   [Full Text] [Related]  

  • 29. Comparison of the safety of standard and triple dose gadodiamide injection in MR imaging of the central nervous system. A double-blind study.
    Svaland MG; Christensen T; Lundorf E
    Acta Radiol; 1994 Jul; 35(4):396-9. PubMed ID: 8011392
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anaphylactic reaction and cardiac arrest due to gadobenate dimeglumine.
    Virtos M; Ruiz S; Mokrane FZ; Rousseau H; Georges B; Fourcade O; Conil JM
    Anaesth Crit Care Pain Med; 2015 Aug; 34(4):247-8. PubMed ID: 26004876
    [No Abstract]   [Full Text] [Related]  

  • 31. Severe adverse reaction to iv gadopentetate dimeglumine.
    Takebayashi S; Sugiyama M; Nagase M; Matsubara S
    AJR Am J Roentgenol; 1993 Mar; 160(3):659. PubMed ID: 8430574
    [No Abstract]   [Full Text] [Related]  

  • 32. Nonionic magnetic resonance imaging contrast agents. Clinical trial experience of safety, tolerance, and efficacy of gadodiamide injection.
    Van Wagoner M; O'Toole M; Quay SC
    Invest Radiol; 1990 Sep; 25 Suppl 1():S39-41. PubMed ID: 2283251
    [No Abstract]   [Full Text] [Related]  

  • 33. A double-blind, comparative study of gadodiamide injection and gadopentetate dimeglumine in MRI of the central nervous system.
    Valk J; Algra PR; Hazenberg CJ; Slooff WB; Svaland MG
    Neuroradiology; 1993; 35(3):173-7. PubMed ID: 8459913
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Gadolinium-DTPA (Magnevist) as contrast medium for arterial DSA].
    Schild HH; Weber W; Boeck E; Mildenberger P; Strunk H; Düber C; Grebe P; Schadmand-Fischer S; Thelen M
    Rofo; 1994 Mar; 160(3):218-21. PubMed ID: 8136474
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of contrast media for magnetic resonance imaging.
    Goldstein HA; Wiggins JR; Kashanian F
    Ann N Y Acad Sci; 1992 Mar; 649():322-31. PubMed ID: 1580503
    [No Abstract]   [Full Text] [Related]  

  • 36. Clinical safety of gadopentetate dimeglumine.
    Nelson KL; Gifford LM; Lauber-Huber C; Gross CA; Lasser TA
    Radiology; 1995 Aug; 196(2):439-43. PubMed ID: 7617858
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Severe anaphylactoid reaction to Gd-DTPA.
    Lufkin RB
    Radiology; 1990 Sep; 176(3):879. PubMed ID: 2389057
    [No Abstract]   [Full Text] [Related]  

  • 38. A phase I clinical trial with gadodiamide injection, a nonionic magnetic resonance imaging enhancement agent.
    VanWagoner M; O'Toole M; Worah D; Leese PT; Quay SC
    Invest Radiol; 1991 Nov; 26(11):980-6. PubMed ID: 1743922
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical experience with gadodiamide injection in magnetic resonance imaging of the central nervous system.
    Andrew E; Svaland M; Lundby B; Hugo F; LaFrance N
    Invest Radiol; 1994 Jun; 29 Suppl 2():S186-8. PubMed ID: 7928225
    [No Abstract]   [Full Text] [Related]  

  • 40. Anaphylactic shock induced by intravenous gadopentetate dimeglumine.
    Tardy B; Guy C; Barral G; Page Y; Ollagnier M; Bertrand JC
    Lancet; 1992 Feb; 339(8791):494. PubMed ID: 1346846
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.